Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

Exosome-Transmitted PSMA3 and PSMA3-AS1 Promotes Proteasome Inhibitors Resistance in Multiple Myeloma

(2019) Hongxia Xu et al.   CLINICAL CANCER RESEARCH

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

(2019) Yuan Xiao Zhu et al.   Blood Cancer Journal

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation

(2019) Nan Zhou et al.   LEUKEMIA

Reprint of “Immunomodulatory effects of CD38-targeting antibodies”

(2019) Niels W.C.J. van de Donk   IMMUNOLOGY LETTERS

The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa

(2019) Laura Moreno et al.   CLINICAL CANCER RESEARCH

A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

(2019) Joseph Mikhael et al.   BLOOD

Daratumumab in multiple myeloma

(2019) Ajay K. Nooka et al.   CANCER

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

(2018) Niels W. C. J. van de Donk et al.   BRITISH JOURNAL OF HAEMATOLOGY

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

(2018) Marjorie Pick et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

(2018) Shaji K. Kumar et al.   Journal of the National Comprehensive Cancer Network

Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway

(2018) Leonhard Busch et al.   LEUKEMIA

Spectrum and functional validation of PSMB5 mutations in multiple myeloma

(2018) Santiago Barrio et al.   LEUKEMIA

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity

(2018) Jiye Liu et al.   LEUKEMIA

Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy

(2018) Elena Zamagni et al.   Expert Review of Hematology

Daratumumab induces CD38 internalization and impairs myeloma cell adhesion

(2018) Jayeeta Ghose et al.   OncoImmunology

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy

(2018) Sophia Danhof et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways

(2017) Sabrina Manni et al.   Journal of Hematology & Oncology

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

(2017) C S Chim et al.   LEUKEMIA

CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma

(2017) Chang-Xin Shi et al.   MOLECULAR CANCER THERAPEUTICS

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner

(2017) Konstantinos Dimopoulos et al.   Molecular Oncology

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

(2017) L. Rasche et al.   Nature Communications

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways

(2017) Sabrina Manni et al.   Oncotarget

Multiple myeloma cells’ capacity to decompose H2O2determines lenalidomide sensitivity

(2016) Sinto Sebastian et al.   BLOOD

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

(2016) A. Jakubowiak et al.   BLOOD

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

(2016) Inger S. Nijhof et al.   BLOOD

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

(2016) K. M. Kortum et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

(2016) Marije B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

(2016) G P Soriano et al.   LEUKEMIA

Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity

(2016) Ruth Eichner et al.   NATURE MEDICINE

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

(2016) Teru Hideshima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

(2016) Dominik Dytfeld et al.   Oncotarget

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors

(2016) Niels E. Franke et al.   Oncotarget

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma

(2016) Jinheng Wang et al.   Oncotarget

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

(2015) L. F. Peterson et al.   BLOOD

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma

(2015) Bingzong Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities

(2015) G. Shay et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

(2015) I S Nijhof et al.   LEUKEMIA

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

(2015) Marije B Overdijk et al.   mAbs

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

(2015) Jan Krönke et al.   NATURE

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model

(2015) Alberto Horenstein et al.   Cells

Heat shock proteins in multiple myeloma

(2015) Lei Zhang et al.   Oncotarget

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells

(2014) J. Wang et al.   BLOOD

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

(2014) Y. X. Zhu et al.   BLOOD

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

(2014) A. Garcia-Gomez et al.   CLINICAL CANCER RESEARCH

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

(2014) Q. Dou et al.   CURRENT CANCER DRUG TARGETS

Pomalidomide for the treatment of relapsed–refractory multiple myeloma: a review of biological and clinical data

(2014) Massimo Offidani et al.   Expert Review of Anticancer Therapy

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

CSNK1α1 mediates malignant plasma cell survival

(2014) Y Hu et al.   LEUKEMIA

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

(2014) E M Ocio et al.   LEUKEMIA

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

(2014) Eric S. Fischer et al.   NATURE

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

(2013) Daniel Heintel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

(2013) Shauna M. Collins et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

(2013) A Thakurta et al.   LEUKEMIA

The clinical significance of cereblon expression in multiple myeloma

(2013) Steven R. Schuster et al.   LEUKEMIA RESEARCH

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma

(2012) Jing-li Gu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

(2012) Matthew Hoffmann et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs

(2012) Enrique M Ocio et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

(2012) M A Hurchla et al.   LEUKEMIA

Blocking Autophagy Prevents Bortezomib-Induced NF-κB Activation by Reducing I-κBα Degradation in Lymphoma Cells

(2012) Li Jia et al.   PLoS One

Discovery and Development of Second-Generation Proteasome Inhibitors

(2012) Christopher J. Kirk   SEMINARS IN HEMATOLOGY

IMiD immunomodulatory compounds block C/EBP  translation through eIF4E down-regulation resulting in inhibition of MM

(2011) S. Li et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects

(2011) Nianhang Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen

(2011) Lü Shuqing et al.   EXPERIMENTAL HEMATOLOGY

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells

(2011) Mu Hao et al.   Journal of Hematology & Oncology

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

(2011) N E Franke et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy

(2011) Patricia Balsas et al.   LEUKEMIA RESEARCH

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

(2010) D. Chauhan et al.   BLOOD

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

(2010) Lawrence R. Dick et al.   DRUG DISCOVERY TODAY

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients

(2010) M. Zangari et al.   HAEMATOLOGICA

Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

(2010) Chad C. Bjorklund et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

(2010) M Ri et al.   LEUKEMIA

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib

(2009) M. Milani et al.   CANCER RESEARCH

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

(2009) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Mechanisms of proteasome inhibitor action and resistance in cancer

(2008) David J. McConkey et al.   DRUG RESISTANCE UPDATES

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD